You are here: Industry Insights > gilead

News List

Gilead, Precision to co-develop hepatitis B therapies pharmatimes
September 18, 2018
Gilead and Precision BioSciences are to work together on developing gene-editing treatments against hepatitis B.
Gilead offloads experimental myelofibrosis drug momelotinib to Sierra Oncology for just $3 million upfront firstwordpharma
August 23, 2018
Gilead Sciences sold its experimental drug momelotinib to Sierra Oncology for an upfront fee of $3 million, as well as potential milestone payments of up to $195 million, the latter company announced Wednesday.
With just $3M upfront, Sierra buys an unwanted Gilead late-stage cancer drug fiercebiotech
August 23, 2018
Gilead paid billions to get into the CAR-T game with its purchase of Kite Pharma, and now it's looking to offload some unwanted cancer assets.
Andrew Cheng to quit Gilead 6 months after taking CMO post fiercebiotech
August 16, 2018
Andrew Cheng, M.D., Ph.D., is set to leave Gilead six months after being appointed CMO. Cheng’s swift exit keeps the revolving door spinning at the top of Gilead, which is set to lose its CEO, CMO, CSO and executive chairman over a nine-month window.
Gilead investors see Celgene veteran Jackie Fouse as top pick for CEO spot: analyst fiercepharma
August 01, 2018
Biotech investors may still be getting over the shock of the departure of Gilead’s top two executives, but that hasn’t stopped analysts from speculating about who will be the troubled company’s next CEO.
Gilead's top executives Milligan and Martin stepping down fiercepharma
July 27, 2018
In a clean sweep, the two top executives at Gilead Sciences will step down, setting the struggling company up for an entirely new direction.
Gilead’s Kite bags option to buy gamma delta startup Gadeta fiercebiotech
July 23, 2018
Gilead’s Kite Pharma has snagged an option to buy gamma delta T-cell receptor (TCR) startup Gadeta. The deal sees Kite take a stake in Gadeta and commit to milestones tied to the progress of oncology candidates.
Jefferies says Gilead is poised for turnaround—and JAK inhibitor could be key fiercebiotech
July 09, 2018
Gilead Sciences is eagerly awaiting phase 3 data for its rheumatoid arthritis drug filgotinib in the next few weeks that could be an antidote for the biotech’s hepatitis C hangover.
CAR-T race heads to Europe as Gilead, Novartis drugs score CHMP backing fiercepharma
July 02, 2018
Months after Novartis and Gilead Sciences won their CAR-T approvals in the U.S., the companies have scored CHMP recommendations for Kymriah and Yescarta in Europe.
Gilead, Hookipa pen hepatitis B, HIV research collaboration fiercebiotech
June 11, 2018
Gilead has licensed immunization technologies from Hookipa Biotech for use against hepatitis B and HIV. The big biotech is paying $10 million (€8.5 million) upfront and committing to milestones that could exceed $400 million to snag exclusive rights to tw

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page